Novavax Opens Its First U.S. Vac...(ith complexinfrastructure the Novavax fa...)

Date:5/1/2008

ith complex infrastructure, the Novavax facility employs unique cell-based technology and disposable manufacturing systems which require less production infrastructure and represent a simpler and potentially more efficient approach to vaccine production. The novel methods being applied at Novavax's new facility will enable the company to produce vaccines within twelve weeks of flu strain identification, which is less than half the time required by current manufacturers of approved vaccines. These methods should also enable the company to respond faster to seasonal or pandemic flu outbreaks once the vaccines in development are approved.

Novavax has four proprietary vaccine candidates in development addressing pandemic influenza, seasonal flu, varicella zoster and an undisclosed infectious disease target. The company's lead vaccine candidate to protect against pandemic influenza is currently in Phase II clinical testing.

"I congratulate Novavax on the opening of this impressive facility and wish them continued success in developing innovative, vital vaccines to prevent infectious diseases such as influenza," said Montgomery County Executive Isiah Leggett. "We are very pleased to have Novavax headquartered in Montgomery County, as they are certainly one of our brightest, most promising biotechnology companies and we look forward to their continued growth and success."

"Novavax's decision to relocate their corporate headquarters to Maryland and expand with this new state-of-the-art vaccine production facility is a tremendous win for both Montgomery County and the State of Maryland," said David W. Edgerley, Secretary of the Maryland Department of Business and Economic Development. "This new facility will not only build on Governor O'Malley's vision to strengthen our State's reputation as a bioscience powerhouse, but also puts Maryland on the forefront of disease control and prevention."

About Novavax

Novavax, Inc. is a clinical stage bi
'/>"/>

SOURCE Novavax, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Novavax CEO to Present at the World Vaccine Congress 2008
2. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
3. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
4. Novavax CEO to Present at BIO CEO & Investor Conference
5. Cytochroma opens U.S. headquarters in Illinois
6. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
7. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
8. Transgenomic Opens Pharmacogenomics Laboratory in China
9. Finesse Solutions Opens New E-Store for Sensors
10. GRAS Status Opens Door to U.S. Food Industry
11. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK